Oncology & Cancer

New study finds two-drug combo slows advanced pancreatic cancer

The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found. This was ...

Oncology & Cancer

New boost for pancreatic cancer therapy

Scientists at Fox Chase Cancer Center are developing a new way to treat pancreatic cancer by boosting the effects of gemcitabine (Gemzar)—the chemotherapy drug that is considered standard therapy for the disease. Although ...

Oncology & Cancer

Scientists break through pancreas cancer treatment barrier

Pancreas cancer tumors spread quickly and are notoriously resistant to treatment, making them among the deadliest of malignancies. Their resistance to chemotherapy stems in part from a unique biological barrier the tumor ...

Oncology & Cancer

Combination therapy may enhance gemcitabine activity

Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer ...

Oncology & Cancer

Less-toxic chemo improves outlook for advanced bladder cancer

(Medical Xpress) -- New data from the University of Rochester Medical Center confirms that an easier, two-drug chemotherapy regimen given to bladder cancer patients prior to surgery shrinks locally advanced tumors and completely ...

page 4 from 5